Ottiliavej 9 DK-2500 Valby København Tel +45 36 30 13 11 Fax +45 36 43 82 62 E-mail investor@lundbeck.com www.lundbeck.com



Release No 290

31 August 2007

Total number of voting rights and size of share capital in H. Lundbeck A/S as of 31 August 2007

In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, H. Lundbeck A/S is required to publish the total number of voting rights and the size of the share capital in H. Lundbeck A/S at the end of each calendar month where there has been a change.

The share capital in H. Lundbeck A/S consists of one class of shares and as of 31 August 2007 the share capital amounts to DKK 1,036,398,155 divided into 207,279,631 shares of DKK 5 each and 207,279,631 votes.

Lundbeck contacts

Investors: Media:

Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187

Stock Exchange Release No 290 – 31 August 2007

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com